Initial 100 consecutive stereotactic core breast biopsies in a private breast center setting

Breast biopsy techniques have evolved to include less invasive alternatives to traditional surgical methods. Open surgical biopsy remains a standard diagnostic tool but involves greater risk and recovery time. Prior research has shown that percutaneous approaches can reduce patient discomfort and hospital stays. However, diagnostic accuracy remains a concern in non-surgical methods. No prior work had resolved whether stereotactic core biopsy could match surgical biopsy in diagnostic reliability. This gap motivated exploration of stereotactic techniques in real-world clinical settings. The transition from surgical to image-guided biopsies requires validation in diverse patient populations. A private breast center setting offers a practical test environment for such procedures. This paper's contribution lies in assessing the initial outcomes of a new biopsy method.

The study aimed to evaluate the performance of stereotactic core biopsy in a private breast center. Three surgeons performed the first 100 consecutive procedures to test clinical feasibility. The goal was to determine whether this method could reliably detect benign and malignant lesions. The motivation stemmed from the need for less invasive diagnostic options. Early detection of breast cancer remains a priority in oncology. The team sought to confirm diagnostic accuracy against open biopsy results. A focus on real-world outcomes ensures relevance to clinical practice. This approach supports decision-making in diagnostic pathways.

The research team conducted 100 consecutive stereotactic core biopsies in a private breast center. Three surgeons performed the procedures using standard imaging and biopsy tools. Lesions were categorized as benign or malignant based on histological results. Follow-up open biopsies were performed in selected cases to confirm findings. Histological agreement was assessed between stereotactic and surgical results. One case involved a discrepancy requiring further pathological review. The study tracked procedural safety and patient outcomes. No novel tools or protocols were introduced during the process.

Of the 100 biopsies, 89 showed benign results and 11 showed malignancy. Histological agreement occurred in ten malignant and eight benign cases confirmed by open biopsy. One case initially diagnosed as sclerosing papilloma was later found to be low-grade ductal carcinoma in situ. The overall accuracy of stereotactic biopsy was high in this cohort. No major procedural complications were reported during the study period. The method demonstrated cost-effectiveness compared to surgical alternatives. Patient recovery times were shorter than traditional biopsy approaches. These findings suggest strong diagnostic reliability in clinical practice.

The authors state that stereotactic core biopsy is safe and accurate in their clinical setting. They report high agreement with open biopsy results in most cases. The procedure may become the preferred diagnostic method for breast lesions. Cost and recovery advantages support its adoption in private centers. The one case of diagnostic discrepancy highlights the need for careful interpretation. The study does not claim superiority over all surgical methods but suggests equivalence. The findings suggest potential for broader clinical implementation. These conclusions align directly with the authors' stated outcomes.